NovaBridge Biosciences ADR
NovaBridge Biosciences ADR (NBP) Option Chain
As of October 2, 2026, NovaBridge Biosciences ADR is trading at $1.36, a +0.37% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 115.3%. IV Rank is —%.
Read more
Tracking the NBP option chain helps you see every strike and expiry on NovaBridge Biosciences ADR in one view, so you can quickly identify the contracts that fit your thesis and your risk. NovaBridge Biosciences ADR's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of NBP options activity at a glance. Use our scanner to monitor the NBP option chain in real time and filter for the NBP options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For NBP stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the NBP option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where NBP stock options are being actively traded and where they are not.
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor.
The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls NovaBridge Biosciences ADR's full chain across every expiry, highlights the most liquid strikes, and lets you screen NBP options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of NBP stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile—
- Market cap (M$)158
- 52 weeks high-79.97%
- 52 weeks low3.82%
- Analyst recommendationStrong Buy
1.00 - Target price$9.00
561.76% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-0.44
- EPS growth next 5 years—
As of October 2, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 100.00 | 652 | 0 | 0.75 | 0.00 | — | 0.75 | 2.50 | +83.82 | — | 4.90 | 1.14 | 3.76 | 0 | 0 | 0.00 |
| 100.00 | 54 | 0 | 0.65 | 0.00 | — | 0.65 | 5.00 | +267.65 | 1.20 | 6.00 | 3.64 | -0.04 | 0 | 0 | 0.00 |
| 100.00 | 111 | 0 | 0.65 | 0.00 | — | 0.65 | 7.50 | +451.47 | 3.70 | 8.50 | 6.14 | -0.04 | 0 | 0 | 0.00 |
As of October 2, 2026
Scan the full option chain in one place
Browse the full NBP option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→